Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Current Liabilities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Total Current Liabilities for 11 consecutive years, with $14.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 34.99% to $14.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.9 million through Dec 2025, down 34.99% year-over-year, with the annual reading at $14.9 million for FY2025, 34.99% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $14.9 million at Cartesian Therapeutics, up from $13.8 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $95.6 million in Q3 2021, with the low at $12.3 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $38.4 million, with a median of $26.3 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities soared 287.81% in 2021, then tumbled 75.18% in 2022.
  • Over 5 years, Total Current Liabilities stood at $72.3 million in 2021, then plummeted by 65.29% to $25.1 million in 2022, then surged by 172.0% to $68.2 million in 2023, then tumbled by 66.32% to $23.0 million in 2024, then tumbled by 34.99% to $14.9 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $14.9 million, $13.8 million, and $12.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.